Published in ACS Nano on September 28, 2016
Mimicking Tumors: Toward More Predictive In Vitro Models for Peptide- and Protein-Conjugated Drugs. Bioconjug Chem (2017) 0.78
Fibroblasts in cancer. Nat Rev Cancer (2006) 18.95
Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell (2014) 5.87
Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. Cancer Cell (2014) 5.38
Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Anal Biochem (2005) 4.65
Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res (2006) 4.43
Multicellular tumor spheroids: an underestimated tool is catching up again. J Biotechnol (2010) 4.33
Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size. Nat Nanotechnol (2011) 4.22
Identification of fibroblast heterogeneity in the tumor microenvironment. Cancer Biol Ther (2006) 4.20
Engineering tumors with 3D scaffolds. Nat Methods (2007) 3.96
Mechanics of receptor-mediated endocytosis. Proc Natl Acad Sci U S A (2005) 3.78
Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles. Biomaterials (2010) 3.54
Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B. Nat Med (2012) 3.21
Tumor stromal architecture can define the intrinsic tumor response to VEGF-targeted therapy. Clin Cancer Res (2013) 3.01
Vitamin D receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy. Cell (2014) 2.74
Multifunctional nanoparticles: cost versus benefit of adding targeting and imaging capabilities. Science (2012) 2.73
Anisamide-targeted stealth liposomes: a potent carrier for targeting doxorubicin to human prostate cancer cells. Int J Cancer (2004) 2.31
Improvement of cancer-targeting therapy, using nanocarriers for intractable solid tumors by inhibition of TGF-beta signaling. Proc Natl Acad Sci U S A (2007) 2.30
Fibroblast heterogeneity in the cancer wound. J Exp Med (2014) 2.09
Tuning payload delivery in tumour cylindroids using gold nanoparticles. Nat Nanotechnol (2010) 2.01
Prognostic gene-expression signature of carcinoma-associated fibroblasts in non-small cell lung cancer. Proc Natl Acad Sci U S A (2011) 1.88
Combining two strategies to improve perfusion and drug delivery in solid tumors. Proc Natl Acad Sci U S A (2013) 1.83
Micropharmacology of monoclonal antibodies in solid tumors: direct experimental evidence for a binding site barrier. Cancer Res (1992) 1.81
Size-dependent localization and penetration of ultrasmall gold nanoparticles in cancer cells, multicellular spheroids, and tumors in vivo. ACS Nano (2012) 1.62
Strategies for advancing cancer nanomedicine. Nat Mater (2013) 1.48
Impact of single-chain Fv antibody fragment affinity on nanoparticle targeting of epidermal growth factor receptor-expressing tumor cells. J Mol Biol (2007) 1.48
Diffusion of particles in the extracellular matrix: the effect of repulsive electrostatic interactions. Biophys J (2010) 1.47
Transport of fluid and macromolecules in tumors. III. Role of binding and metabolism. Microvasc Res (1991) 1.43
Pancreatic cancer stroma: friend or foe? Cancer Cell (2014) 1.25
Staging and reporting of urothelial carcinoma of the urinary bladder. Mod Pathol (2009) 1.24
A highly efficient synthetic vector: nonhydrodynamic delivery of DNA to hepatocyte nuclei in vivo. ACS Nano (2013) 1.22
Role of stromal myofibroblasts in invasive breast cancer: stromal expression of alpha-smooth muscle actin correlates with worse clinical outcome. Breast Cancer (2010) 1.21
Docetaxel conjugate nanoparticles that target α-smooth muscle actin-expressing stromal cells suppress breast cancer metastasis. Cancer Res (2013) 1.08
Lipid-coated Cisplatin nanoparticles induce neighboring effect and exhibit enhanced anticancer efficacy. ACS Nano (2013) 1.07
Early intervention in cancer using monoclonal antibodies and other biological ligands: micropharmacology and the "binding site barrier". Cancer Res (1992) 1.00
Codelivery of VEGF siRNA and gemcitabine monophosphate in a single nanoparticle formulation for effective treatment of NSCLC. Mol Ther (2013) 0.98
Altered iron metabolism, transferrin receptor 1 and ferritin in patients with colon cancer. Cancer Lett (2005) 0.97
In vivo distribution of polymeric nanoparticles at the whole-body, tumor, and cellular levels. Pharm Res (2010) 0.96
Engineered culture models for studies of tumor-microenvironment interactions. Annu Rev Biomed Eng (2013) 0.95
Solid tumor penetration by integrin-mediated pegylated poly(trimethylene carbonate) nanoparticles loaded with paclitaxel. Biomaterials (2012) 0.91
Influence of polyethylene glycol density and surface lipid on pharmacokinetics and biodistribution of lipid-calcium-phosphate nanoparticles. Biomaterials (2014) 0.89
Differential expression of cancer-associated fibroblast-related proteins according to molecular subtype and stromal histology in breast cancer. Breast Cancer Res Treat (2015) 0.87
Targeted PRINT Hydrogels: The Role of Nanoparticle Size and Ligand Density on Cell Association, Biodistribution, and Tumor Accumulation. Nano Lett (2015) 0.86
Effects of tumor microenvironment heterogeneity on nanoparticle disposition and efficacy in breast cancer tumor models. Clin Cancer Res (2014) 0.86
Lipid-calcium phosphate nanoparticles for delivery to the lymphatic system and SPECT/CT imaging of lymph node metastases. Biomaterials (2014) 0.85
Orchestrating the Tumor Microenvironment to Improve Survival for Patients With Pancreatic Cancer: Normalization, Not Destruction. Cancer J (2015) 0.81